DISEASE CHARACTERISTICS:

• One of the following diagnoses:

  • Acute myelogenous leukemia (AML) meeting 1 of the following conditions:

    • Failed to achieve first remission after an intensive induction regimen containing an anthracycline and cytarabine
    • In second remission and not enrolled in a protocol for autologous bone marrow transplantation
    • Failed to achieve or sustain second remission

    • In first remission but at high risk of relapse because of 1 of the following factors:

      • High-risk cytogenetic features (monosomy 7,5q-, trisomy 8, or t(9;22))
      • AML secondary to treatment of a prior malignancy and without good-risk cytogenetic features of t(8;21), t(15;17), or inv 16
      • AML secondary to myelodysplastic disease

  • Acute lymphocytic leukemia (ALL) meeting 1 of the following conditions:

    • In second remission with initial relapse occurring within 2 years of diagnosis
    • In first complete remission with high-risk cytogenetics (t(9;22) or t(4;11))
    • In third or subsequent remission
    • Failed to achieve or sustain a second remission
  • Chronic myelogenous leukemia (CML) in first or second chronic phase or accelerated phase
  • Stage IV lymphoblastic lymphoma not in first remission or that failed to achieve a remission within the first 4 weeks of induction therapy
  • Juvenile CML
  • Myelodysplastic syndrome
  • Severe aplastic anemia unresponsive to anti-thymocyte globulin or cyclosporine
• No CNS or skin involvement with leukemia
• No requirement for mediastinal irradiation
• No healthy, HLA-identical related donor of at least 1 year of age or matched unrelated donor available within 4-6 months

• Availability of a healthy, 1-3 HLA-A, -B, and -DR mismatched related donor

  • Willing and able to undergo general anesthesia for marrow donation and a 5-day course of filgrastim (G-CSF) with 2 daily leukaphereses

PATIENT CHARACTERISTICS:

Age:

• Under 50 (50 and over allowed on a case-by-case basis)

Performance status:

• Age 16 and over:

  • Karnofsky 70-100%

• Under age 16:

  • Lansky 50-100%

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL (in the absence of liver involvement)
• AST less than twice normal (in the absence of liver involvement)

Renal:

• Creatinine normal OR
• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• Asymptomatic or LVEF greater than 50% at rest, with improvement during exercise

Pulmonary:

• Asymptomatic or DLCO greater than 50% predicted (corrected for hemoglobin)

Other:

• No known hypersensitivity to mouse protein or chicken egg products
• No active viral, bacterial, or fungal infection
• HIV-1, HIV-2, HTLV-1, and HTLV-2 negative
• No other concurrent medical condition that would preclude transplantation
• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

Surgery

• See Disease Characteristics